What does an estrogen receptor (ER) Allred score of 4 out of 8 indicate?

ER 4/8 Allred Score Interpretation

An Allred score of 4/8 indicates weakly ER-positive breast cancer (1-10% positive cells with weak intensity), which should be reported as "ER Low Positive" and treated with caution regarding endocrine therapy benefit. 1

Understanding the Allred Score

The Allred scoring system combines:

• Proportion Score (PS): Percentage of positive cells (0-5)
• Intensity Score (IS): Staining intensity (0-3)
• Total Score (TS): PS + IS = 0-8

An Allred score of 4/8 typically represents:

• Low percentage of positive cells (1-10%)
• Weak to moderate staining intensity
• Falls into the "ER Low Positive" category per current ASCO/CAP guidelines 1

Clinical Significance and Treatment Implications

This is a biologically distinct subgroup that behaves more like ER-negative disease despite technical positivity. The 2020 ASCO/CAP guidelines specifically created the "ER Low Positive" reporting category for tumors with 1-10% staining because:

• These cancers have molecular profiles more similar to ER-negative/triple-negative breast cancer than to strongly ER-positive tumors 1
• Clinical outcomes and prognosis resemble ER-negative disease 2, 3
• Limited evidence exists for endocrine therapy benefit in this range 1

Evidence for Endocrine Therapy

The key data comes from a 2011 meta-analysis of 20 trials with >200,000 women-years of follow-up:

• Tumors with very low ER (equivalent to <1% by IHC): no benefit from tamoxifen
• Tumors with low ER (10-20 fmol/mg by ligand-binding assay, roughly corresponding to 1-10% by IHC): 33% reduction in recurrence risk (RR 0.67) with 5 years of tamoxifen 1

However, this benefit is substantially less than the 48% reduction (RR 0.52) seen in high ER expressors 1.

Recommended Approach

The pathology report should include:

1. Designation as "ER Low Positive"
2. Specific percentage of positive cells
3. Intensity of staining
4. Status of controls
5. A comment explaining the limited clinical data and heterogeneous biology 1

Clinical management considerations:

• Consider treating more like triple-negative breast cancer regarding chemotherapy decisions 3
• Endocrine therapy may still be offered given relatively low toxicity, but discuss limited benefit data with patient 1
• These patients should ideally be included in triple-negative breast cancer clinical trials, including immune-chemotherapy regimens 3
• Do not assume equivalent benefit to strongly ER-positive disease (>10% staining) 2, 4

Important Caveats

Quality control is critical for low-positive results:

• Verify external and internal controls worked appropriately 1
• Consider second pathologist review 1
• Document preanalytic variables (fixation time, type) 1
• If result is unexpected, consider retesting on different block 1

Prognostic implications:

• Research shows that ER expression around 45-50% represents an inflection point, with tumors below this threshold having worse prognosis 5
• An Allred score of 4/8 falls well below this threshold, indicating higher recurrence risk 2, 5

The key message: ER 4/8 is technically positive but clinically behaves more like ER-negative disease, warranting aggressive systemic therapy consideration rather than relying primarily on endocrine therapy.